Arvinas Stock Price, News & Analysis

Arvinas, a clinical-stage biopharmaceutical firm, announced significant updates in its latest press release. The company has initiated Phase 2 dosing for ARV-110 and continues dose escalation for ARV-110 and ARV-471 trials. A collaboration with Pfizer will lead to a Phase 1b trial combining ARV-471 with Ibrance, expected to start fourth quarter 2020. Financial results for Q3 2020 highlighted a net loss of $30.8 million, an increase from $17.7 million in Q3 2019, amid rising R&D expenses of $30.0 million. Cash reserves were $248.6 million, sufficient to support operations into 2022.

Arvinas, Inc. (Nasdaq: ARVN) announced significant updates to its preclinical pipeline, revealing five new programs targeting oncology, immuno-oncology, and neuroscience. The company aims to enhance its leadership in targeted protein degradation with its PROTAC® Discovery Engine. Key targets include BCL6, KRAS, Myc, HPK1, and mHTT, with plans to file INDs by 2022 and 2023. Clinical trials are ongoing for ARV-110 and ARV-471, with data updates expected in Q4 2020. This expansion underscores Arvinas' commitment to addressing high unmet medical needs in various disease areas.

Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), will have its President and CEO, John Houston, Ph.D., present at the 3rd Annual Targeted Protein Degradation Summit on October 14-15, 2020. The session, titled "The Promise of PROTAC® Protein Degraders: What’s Next for Arvinas’ Pipeline & Platform," will showcase advancements in Arvinas' PROTAC® technology and introduce new pipeline programs. The company focuses on developing therapies that degrade disease-causing proteins, with two clinical-stage programs targeting advanced prostate and breast cancers.

Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), announced that its Chief Scientific Officer, Ian Taylor, Ph.D., will participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on September 10 at 2:25 p.m. ET. A live audio webcast will be available here and on Arvinas’ website. The company is focused on developing therapies for diseases like metastatic prostate cancer and ER+/HER2- breast cancer.

Arvinas, Inc. (Nasdaq: ARVN) has appointed Wendy Dixon, Ph.D., to its Board of Directors, enhancing its leadership with her 40 years of biopharmaceutical experience. Dr. Dixon, recognized for her successful product launches, will provide strategic insight into marketing and business development as Arvinas advances its targeted protein degradation therapies. The company’s two clinical-stage programs, ARV-110 for prostate cancer and ARV-471 for ER+/HER2- breast cancer, are pivotal to its mission of improving patient lives.

Arvinas, a clinical-stage biotechnology company, has appointed Linda Bain to its Board of Directors. Bain, currently CFO of Codiak BioSciences, brings extensive financial and operational experience from previous roles at Avalanche Biotechnologies and bluebird bio, among others. Arvinas' CEO, John Houston, noted her expertise will be vital as the company advances its PROTAC platform, aimed at degrading disease-causing proteins. Arvinas has two clinical programs targeting prostate and breast cancer, reinforcing its commitment to innovative therapeutic solutions.

On June 5, 2020, Arvinas (Nasdaq: ARVN) announced Dr. Ron Peck, Chief Medical Officer, will speak at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11 at 4:40 p.m. ET. A live audio webcast will be available here and on their website at www.arvinas.com.

Arvinas, Inc. (Nasdaq: ARVN) has announced that its 2020 Annual Meeting of Stockholders will be held virtually on June 3, 2020, at 8:30 AM ET. This change is due to the COVID-19 pandemic and related restrictions. Stockholders as of April 6, 2020, are eligible to participate and vote. Registration is required by May 31, 2020, through the Annual Meeting Website. The company encourages all stockholders to vote in advance. Arvinas is focused on developing therapies that degrade disease-causing proteins, with clinical-stage programs targeting prostate and breast cancer.

Arvinas, Inc. (Nasdaq: ARVN) has announced updated safety and efficacy data for ARV-110, a PROTAC protein degrader, during the upcoming 2020 ASCO Annual Meeting. The Phase 1/2 trial targets men with metastatic castration-resistant prostate cancer, showing promising results, including ongoing PSA responses in two patients. The trial has successfully enrolled patients heavily pre-treated with standard therapies such as enzalutamide and abiraterone. Data highlights a sustained safety profile supporting further dose escalation, marking a significant milestone for Arvinas' innovative therapeutic approach.